Literature DB >> 21128934

High risk of cardiovascular disease in iron overload patients.

Tomás Meroño1, Leonardo Gómez, Leonardo G Rosso, Patricia Sorroche, Laura Boero, Jorge Arbelbide, Fernando Brites.   

Abstract

INTRODUCTION: Iron overload (IO) is defined as an increase in storage iron, regardless of the presence or absence of tissue damage. Whether increased iron stores are involved in the pathogenesis of cardiovascular disease remains controversial.
OBJECTIVES: To study insulin resistance markers, lipoprotein profile, activities of anti and prooxidant enzymes and cholesteryl ester transfer protein (CETP) in patients with IO.
METHODS: Twenty male patients with IO were compared with 20 sex- and age-matched controls. General biochemical parameters, lipoprotein profile, and activities of paraoxonase 1, employing two substrates, paraoxon (PON) and phenylacetate (ARE), lipoprotein-associated phospholipase A(2) (Lp-PLA(2) ) and CETP were determined.
RESULTS: IO patients showed higher levels of HOMA-IR and triglycerides [median (Q1-Q3)] [128 (93-193) vs. 79(51-91) mg dL(-1) , P < 0·0005] while lower high-density lipoprotein (HDL) cholesterol (mean ± SD) (41 ± 9 vs. 52 ± 10 mg dL(-1) , P < 0·0005) in comparison with controls. Moreover, the triglycerides/HDL-cholesterol [3·2 (2·0-5·1) vs. 1·5 (1·0-1·9), P < 0·0005] ratio and oxidized low-density lipoprotein levels [94 (64-103) vs. 68 (59-70) IU L(-1) , P < 0·05] were increased in the patient group. Although no difference was observed in ARE activity, PON activity was decreased in IO patients [246 (127-410) vs. 428 (263-516) nmol mL(-1) min(-1) , P < 0·05]. In addition, CETP and Lp-PLA(2) activities were also increased in the patients (189 ± 31 vs. 155 ± 36% ml(-1)  h(-1) , P < 0·005; and 10·1 ± 2·9 vs. 8·2 ± 2·4 μmol mL(-1) h(-1) , P < 0·05, respectively). Associations between ferritin concentration and the alterations in lipid metabolism were also found. Multiple regression analyses identified HOMA-IR as independent predictor of CETP activity (B = 65·9, P < 0·0001, r(2) = 0·35), as well as ferritin concentration of Lp-PLA(2) activity (B = 3·7, P < 0·0001, r(2) = 0·40) after adjusting for confounding variables.
CONCLUSIONS: IO patients presented not only insulin resistance but also metabolic alterations that were related to elevated iron stores and are associated with high risk of cardiovascular disease.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21128934     DOI: 10.1111/j.1365-2362.2010.02429.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  12 in total

1.  Washing older blood units before transfusion reduces plasma iron and improves outcomes in experimental canine pneumonia.

Authors:  Irene Cortés-Puch; Dong Wang; Junfeng Sun; Steven B Solomon; Kenneth E Remy; Melinda Fernandez; Jing Feng; Tamir Kanias; Landon Bellavia; Derek Sinchar; Andreas Perlegas; Michael A Solomon; Walter E Kelley; Mark A Popovsky; Mark T Gladwin; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

2.  The impact of iron content in a diet high in fat, fructose, and salt on metabolic state and mineral status of rats.

Authors:  Joanna Suliburska
Journal:  J Physiol Biochem       Date:  2013-07-20       Impact factor: 4.158

Review 3.  Iron-induced fibrin in cardiovascular disease.

Authors:  Boguslaw Lipinski; Etheresia Pretorius
Journal:  Curr Neurovasc Res       Date:  2013-08       Impact factor: 1.990

4.  Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice.

Authors:  Motoko Kawashima; Tetsuya Kawakita; Takaaki Inaba; Naoko Okada; Masataka Ito; Shigeto Shimmura; Mitsuhiro Watanabe; Ken Shinmura; Kazuo Tsubota
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

Review 5.  Iron: protector or risk factor for cardiovascular disease? Still controversial.

Authors:  Carlos Muñoz-Bravo; Mario Gutiérrez-Bedmar; Jorge Gómez-Aracena; Antonio García-Rodríguez; Joaquín Fernández-Crehuet Navajas
Journal:  Nutrients       Date:  2013-07-01       Impact factor: 5.717

6.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

7.  Serum ferritin levels and the development of metabolic syndrome and its components: a 6.5-year follow-up study.

Authors:  Päivi Hämäläinen; Juha Saltevo; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala
Journal:  Diabetol Metab Syndr       Date:  2014-10-26       Impact factor: 3.320

Review 8.  The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium.

Authors:  Boguslaw Lipinski; Etheresia Pretorius
Journal:  Front Hum Neurosci       Date:  2013-10-29       Impact factor: 3.169

9.  High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.

Authors:  Janette Bester; Antoinette V Buys; Boguslaw Lipinski; Douglas B Kell; Etheresia Pretorius
Journal:  Front Aging Neurosci       Date:  2013-12-06       Impact factor: 5.750

10.  Deranged iron status in psoriasis: the impact of low body mass.

Authors:  Malgorzata Ponikowska; Malgorzata Tupikowska; Monika Kasztura; Ewa A Jankowska; Jacek C Szepietowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-11-15       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.